Good morning or good afternoon, and welcome to the Healthcare Realty Trust Second Quarter Earnings Conference Call. My name is Adam and I’ll be your operator for today. I will now hand the call over to VP of Investor Relations, Ron Hubbard, to begin. Ron, please go ahead when you are ready.

Thanks, Adam. Thank you for joining us today for Healthcare Realty’s second quarter 2023 earnings conference call. Joining me on the call today are Todd Meredith, Kris Douglas, and Rob Hull. A reminder that except for the historical information contained within, the matters discussed in this call may contain forward-looking statements that involve estimates, assumptions, risks and uncertainties. These risks are more specifically discussed in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2022, and the Form 10-K filed with the SEC for the quarter ended June 30, 2023. These forward-looking statements represent the Company’s judgment as of the date of this call. The Company disclaims any obligation to update this forward-looking material. The matters discussed in this call may also contain certain non-GAAP financial measures such as funds from operations or FFO, normalized FFO, FFO per share, normalized FFO per share, funds available for distribution, or FAD, net operating income, NOI, EBITDA and adjusted EBITDA. A reconciliation of these measures to the most comparable GAAP financial measures may be found in the Company’s earnings press release for the quarter ended June 30, 2023. The Company’s earnings press release, supplemental information and Form 10-Q are available on the Company’s website. I’ll now turn the call over to Todd.

Thank you, Ron, and thank you, everyone, for joining us this morning for our second quarter 2023 earnings call. Healthcare Realty generated steady second quarter operating results. Despite a volatile macro environment, we remain extremely bullish on our ability to capture operational upside from our portfolio. We saw record new leasing activity in the quarter. Robust tours and executed leases are early indicators of the occupancy gains and momentum we expect to see later this year and moving into 2024. We are also refining the portfolio further through asset sales and positioning Healthcare Realty for growth through the formation of a joint venture. On this point, I want to be clear that we are net sellers in this environment. Like many, Healthcare Realty’s current public valuation is not conducive to accretive acquisitions. Our implied cap rate is in the high-6s nearly 7%. This is disconnected with where we’re currently seeing assets trading in the private market. Core strategic assets are trading either side of 6%, some well into the 5s. We are actively selling non-core less strategic assets on average around 6.5%. Given this disconnect, we’re pursuing the sale of non-strategic assets, which also improves the quality of our remaining portfolio. It’s rare when proceeds from non-strategic asset sales can be recycled accretively. We are seizing this window to further refine our portfolio and concentrate on our highest growth properties. We also recently launched a process to form a strategic joint venture. Selling assets into a JV seed portfolio will generate significant proceeds while retaining ownership of strategic properties. These proceeds will more than fund Healthcare Realty’s portion of any go-forward investments. We expect to redeploy meaningful excess proceeds from a seed portfolio into a broad range of options including stock repurchase, debt repayment, development funding, and growth capital to drive occupancy gains. Through the JV, we can generate attractive returns on limited capital and importantly diversify Healthcare Realty’s capital sources. Looking ahead, it also provides a means to invest accretively equably and grow with our healthcare providers who continually need real estate capital and services regardless of capital market conditions. Forming a strategic joint venture in the current environment will position us well for what we expect to be an improving backdrop in 2024. I’ll circle back after Kris and Rob to discuss our leasing momentum and growth outlook. Now, I’ll turn it over to Kris.

Thanks, Todd. Our second quarter operating performance reflects the stability investors have come to know and appreciate from the medical outpatient business. On the macro front, interest rate increases moderated in the second quarter. Despite the moderation, we still experienced a 45 basis-point increase in SOFR compared to the first quarter. This was the primary driver behind the sequential change and normalized FFO per share to $0.39. The FFO for the quarter excludes a one-time benefit of $18 million or approximately $0.05 per share. This was related to a refund of transfer taxes paid in third quarter ’22 and included in merger related costs. Trailing 12-month same-store NOI increased 2.9%. Year-over-year quarterly NOI grew 2.1%. These both benefited from the Company’s share of JVs, which had NOI growth of over 6.5%. We had tremendous success this quarter, maximizing rent growth and occupancy gains to accelerate revenue growth to 3.2% for the quarter. Annual in-place contractual increases now average 2.71%, up 5 basis points from last quarter. The improvement was driven by future contractual increases of 3% for the 1 million square feet of leases that commenced in the quarter. Cash leasing spreads in the quarter also averaged 3%. What is striking is that there are six markets with spreads between 5.6% and 17.8%. For example, Seattle had spreads of 8.7% on over 130,000 square feet of renewals in the last year. This shows the deep pricing power in this market where we have significant scale. Year-over-year average occupancy increased 20 basis points to 89.0% for the same-store properties. Total portfolio of multi-tenant occupancy is just over 85%. The largest opportunity for occupancy gains is in the Legacy HTA multi-tenant portfolio where current occupancy is over 400 basis points below its pre-COVID levels. Returning this portion of the portfolio to pre-COVID levels is more than achievable. This is seen by the fact that legacy HR’s current multi-tenant occupancy of 87.7% is 100 basis points higher than Legacy HTA's pre-COVID levels. We’re already making progress with over 200 basis points of leases and build-out across these HTA properties. As Rob will discuss in more detail, we saw over 375,000 square feet of new leases executed in the quarter. This drove a 30 basis-point sequential improvement in the total portfolio lease percentage. These new leases will drive future absorption as most of these suites move in through the balance of the year. Revenue growth was offset by a 5.3% increase in operating expenses. Net of recoveries, quarterly operating expenses increased 4.7% year-over-year. This is an improvement over what we saw in 2022, but still elevated compared to historical norms of less than 3%. The primary expense driver was continued labor inflation and janitorial and personal expenses, which were up approximately 10%. Looking ahead, we expect labor pressures to subside later in the year. This will allow operating expenses to trim back toward more historical levels as we move into 2024. Maintenance CapEx increased from the seasonal low in the first quarter to 15.1% of NOI in the second quarter. An increase of $8 million in tenant improvement spending is tied to the strong leasing momentum and is expected to continue through the back half of the year. This growth capital is increasing our payout ratio, but we’re comfortable that the payout ratio will come back below 100% as strong NOI growth generated from the positive absorption and underlying portfolio cash flow is realized. Now, a few comments on the updated guidance. FFO guidance for the year was adjusted to a $1.57 to a $1.60 per share. The revision was primarily driven by two separate but related macro factors. First, inflation is moderating, but not as quickly as our original expectations. This is driving higher labor costs and lower operating margins. In addition, interest rates this year are not declining as previously expected. Short-term interest rates in the third and fourth quarter are now projected to be higher than what we experienced in the second quarter before declining in 2024. Additionally, we lowered straight-line rent guidance, a non-cash item, to reflect year to date actual as well as the impact of higher expected dispositions. Our additional disposition guidance was increased to $350 million to $450 million. With over $300 million of dispositions under contract or LOI, we expect to have significant excess proceeds after funding developments and other growth capital. The excess proceeds will be primarily allocated to debt repayment as well as opportunistic share repurchases. The debt repayment will further reduce our floating-rate debt, which is currently 14% of total debt, down from almost 20% a year ago. With this repayment, we expect debt to EBITDA to be in our target range of 6 to 6.5 times. The strength in balance sheet will position us well to capitalize on accelerating same-store and FFO growth in ’24 as the strong leasing activity we’re seeing boosts occupancy.

Thanks, Kris. First I’d like to touch on the increased disposition volumes that Kris mentioned and provide a quick update on the transaction market. The $300 million currently under contract or LOI is expected to close throughout the balance of this year. These sales should be characterized as portfolio cleanup. The properties have lower growth potential and are in areas with little opportunity to build out market scale. As examples, about half of these sales are represented by non-MOB properties. Of the MOBs, most are not part of a cluster. And annual escalators for the group average about 40 basis points lower than HR’s total portfolio. We expect these sales to generate a blended cap rate in the mid-6s. At this level of pricing, this disposition activity reflects a rare moment when we can achieve meaningful portfolio refinement at accretive levels. The transaction market for MOBs continues to be driven by debt costs with some of the larger lenders increasing allocations in the space. All-in lending rates remain around 6%. These rates have steadily held cap rates for core MOB product in the low-6s with higher quality assets pricing below 6%. Now, turning to our leasing activity. New executed leases have increased each month since the beginning of the year when our leasing teams became fully engaged. New leases of 376,000 square feet were signed in the second quarter, up nearly 60% from the first. Tours are strong, positioning us for further gains in new leasing activity in the coming quarters. A disproportionate share of these new leases were completed in the Legacy HTA multi-tenant portfolio. This is a strong indication that the benefits of our third-party brokerage model are beginning to come through. Where we are really seeing the advantages of increased scale is in our 15 largest markets. In these markets, the merger more than doubled the amount of healthcare realty square footage covered by each of our brokerage teams. So such scale provides them with many more options to meet tenant needs. In the quarter, we saw an outsized number of our new leases come from these top 15 markets. For the total portfolio, our executed new leases that are in build-out represent almost 160 basis points of future occupancy. This has expanded 40 basis points from last quarter. The majority of these leases are expected to take occupancy by the end of this year. Regarding broader demand for space, we’ve seen tremendous volume over the past couple of quarters from third-party physician tenants. We are also seeing increased demand from health systems. The for-profit systems have recently reported improving results driven by strong outpatient volume and stabilizing labor costs. For example, HTA and tenant both just reported a second straight quarter of elevated outpatient surgical volumes. We are hearing similar trends among the not-for-profit systems. Looking ahead, we expect health systems to play a greater role in driving our new leasing volumes higher. Where we have seen and where we have already seen increased engagement from health systems is around development. Our development and redevelopment activity totals $339 million of active projects. We added one new development and two new redevelopments this quarter. In Scottsdale, we formed a joint venture with a national developer for an 80% pre-lease, 101,000 square-foot MOB adjacent to a growing HonorHealth campus. The developer saw us as the obvious choice to partner with on this project. Given our significant market presence post-merger. We also commenced two redevelopment projects. One is in Charlotte with Novant Health and the other is in Washington DC near where we own three MOBs on an Inova campus. Both redevelopments came from the HTA portfolio. Across both our leasing and investment opportunities, we are pleased with how much upside potential we see in the HTA portfolio. Now I’ll turn it back over to Todd.

Thank you, Rob. I want to round out our prepared remarks underscoring how leasing momentum is poised to accelerate our growth in ’24. As Rob just described, new leasing volume was especially encouraging in the second quarter. 376,000 square feet of new leases is the highest volume we’ve executed since the merger. And this volume has risen steadily since January. Where it’s really picking up momentum is the HTA multi-tenant portfolio with over 200 basis points of leased versus occupied and an improvement of 60 basis points over first quarter. Since our merger closed last year, we’re seeing two primary drivers elevating our new leasing volume, market scale and relationships. With an average of 29 buildings in our top 15 markets, Healthcare Realty is the obvious first call for providers and brokers. We do a lot of repeat business with providers. As health systems grow their outpatient services, they know we are the most likely owner and developer to be able to immediately address their needs. And with our scale, we do far more leasing transactions than any other owner in these markets. This gives us deeper market knowledge and insight that drives both occupancy and pricing power. Scale also makes us the top priority for our brokerage teams. As Rob indicated the merger more than doubled their portfolios with Healthcare Realty. We are often their most reliable and lucrative client, motivating them to bring more healthcare providers to our buildings. On this note, we’re hosting an Investor Day in Raleigh on October 5th to highlight how market scale and relationships drive leasing momentum, occupancy gains, and rent growth. Those who join will have a chance to tour properties, meet our brokers, and hear from our health system partners. Healthcare Realty’s bright outlook for 2024 growth is largely built on our leasing momentum. We have a tremendous amount of operational upside created by the merger combination. Record new leasing volume will bolster occupancy moving into 2024, especially in the Legacy HTA portfolio. We expect absorption gains to ramp up to a 100 to 200 basis points through the course of 2024. And this has the potential to boost Healthcare Realty’s same-store NOI growth to the 4% to 6% range, which can translate to even more at the FFO per share level. With that, Adam, we’re now ready to shift to the Q&A portion.

And the first question comes from Austin Wurschmidt from KeyBanc Capital Markets.

Just breaking down the change to your same-store NOI guidance. Was there any change to the same-store revenue growth outlook for 2023, or was expenses the sole driver of the 50 basis points decrease to same-store NOI guidance?

Yes. No, it’s really all isolated towards the expense side, which you can see through the updated guidance on our margin as well as then through to the bottom-line same-store NOI growth.

And then you highlighted that a lot of the leasing you’re seeing is in the Legacy HTA portfolio. But I’m curious if those HTA cash leasing spreads are weighing on the combined portfolio and when do you expect the cash leasing spreads to kind of accelerate back to that mid-3% range or better?

Yes. That's the work that we have ahead of us. I want to highlight an interesting observation. When comparing on-campus to off-campus, the cash leasing spreads in the HTA portfolio have been just as strong. In fact, this quarter was slightly stronger than the HR on campus, both in the mid to high-threes. The off-campus segment is trending that way. If we look at the first six months of this year, it's been in the high-1s, nearly 2%. We're observing some softness in the off-campus area, which is true for both the HTA portfolio and HR. However, there’s nothing in the HTA portfolio that would hinder our ability to continue increasing those cash leasing spreads.

Do you expect an acceleration in the back half of the year or 2024 on the combined portfolio?

I think our view is that 3 to 4 range is very consistent. We obviously end up doing a lot of volume each quarter, and even as Kris pointed out some real highlights in a few markets where we had really strong cash leasing spreads. With the volume that we do, it can be difficult to certainly have all of your leases moved to that high-end and push you outside or even above the 3 to 4 range. So I think our view is three to four is still a range that we’re comfortable in and think we can continue to perform in.

The next question comes from Michael Griffin from Citi.

Maybe just asking on operations real quick. I’m curious if guidance has any baked in sort of conservatism in it for this year and then kind of as you look to that 3% to 4% kind of growth range, how achievable you think that is going into next year?

Yes. No, I mean, in terms of the guidance where we’re trying to bring it a little bit tighter based off of where we’re seeing things and what we’re experiencing right now on the labor side as well as what we’re seeing on the interest rate side. I think one of the things that we also took into account is we started to look at where the margins are and overall store NO is what we may experience here in the third quarter as it relates to seasonal utilities given the heat wave that’s coming through. So that’s kind of another piece that we’re trying to take into account that depending on how all that plays out through the remainder of this quarter could shift you a little bit better than maybe what we are planning as of right now. But we’ll have to kind of wait and see how that plays out over the next couple of months.

I just wanted to clarify that our expectation for cash leasing spread is 3% to 4%. However, when discussing same-store performance, we anticipate a 2% to 3% increase this year, and I mentioned that for next year, we are really targeting a range of 4% to 6%.

And then just turning to the dispositions target, did anything change in terms of those non-core dispositions that you highlighted relative to last quarter? Were they not performing up to expectations or any clarity around that would be helpful.

No, I would say it’s very consistent with what we reported last quarter, which was that, based off of what we were seeing where we saw our stock trading on an implied cap basis, that we were going to be leaning into that non-strategic asset sales and that’s what we’ve done and we’re making great progress there with the $300 million that we already have under contract or LOI.

The next question comes from Juan Sanabria from BMO Capital Markets.

Just a question I guess on that leased pipeline and the spread between the lease rate and the occupancy rate. What has that historically been and with the revised guidance, where do you expect occupancy to end the year?

Yes, I would say that historically, it's something we’ve closely monitored at Healthcare Realty, especially since COVID. Initially, it was tracking around 100 basis points, give or take, a bit lower when emerging from COVID. Then it expanded slightly as supply chain issues arose, settling around 100 basis points or less. Currently, in our multi-tenant portfolio, it's at about 160 basis points, and within the HTA portfolio, it's over 200 basis points. This indicates clear potential. We outline in our expected FFO components where we anticipate occupancy changes. We still project 50 to 100 basis points in the multi-tenant sector, although this may be diluted when incorporating single-tenant data. Our focus on leasing momentum and the 376,000 executed leases will largely depend on completing most build-outs by the end of the year. Thus, occupancy could fall within that 50 to 100 range for multi-tenant properties. Regardless, we believe this improvement is underway and should manifest either late in the fourth quarter or into the first quarter, maintaining our outlook of a 50 to 100 basis points improvement at that rate in the multi-tenant sector.

So, that 50 to 100 is kind of a year-end that net absorption number?

Yes.

Is it that number or an average because that you’re running I think at 35 basis points year-to-date?

Yes, I mean really we’re looking at rolling into that sort of by year-end. So obviously, whether that hits exactly at year-end, whether it hits in December or end of December, it will show up in the end of the year. But I think our view is, again, it’s just going to come down to the pace of build-out on some of these. And most of them, as Rob said, we expect a lot of these leases to be done by year-end, but whether or not that hits exactly by December 31st or not, we see it rolling in to getting to that pace as we round the year.

And I would add to that, Todd. Juan, I’d add to that that we’re really focused on the new leasing activity. Todd said it was strong this quarter. And if you look at that level of new leasing activity and the projected move-out kind of that we see going forward, you get to that 50 to 100 basis points. So we feel like we’re at that run rate now. And if you look at the strength of the tours that we’ve seen this year and the level that we have kind of average this year, we think that supports a lot of momentum moving into 2024, and moving us to that level of new leasing that will set us up to accomplish that 100 to 200 basis points of absorption. That’s really where we’re focused is looking to 2024.

And then just as a follow-up, could you comment on what, if anything is assumed in guidance with regards to the JV. You mentioned the process has now started and/or a buyback that seems to be a focal point for proceeds?

I’ll discuss the joint venture, Juan. We currently do not have any guidance related to that for this calendar year. We will incorporate updates into our guidance for 2024 as we make progress. For this year, assume no impact from it. We believe it will take the rest of the year to navigate this process, and whether it closes this year or early next year is not crucial to our guidance. Regarding excess proceeds from asset sales, as Kris mentioned, our first step will be debt repayment. This approach minimizes dilution quickly and might even be accretive. We will also consider share repurchases, especially since the Board reauthorized a significant amount in June. As we receive excess proceeds, we will evaluate them against debt repayment and other funding options we have.

The next question comes from Steven Valiquette from Barclays.

One or two questions here, just around the guidance. I appreciate all the details around the revision. But maybe just with the FFO guidance going down about $0.04 at the midpoint, it wasn’t really crystal clear how much of that could be broken down into the higher operating cost versus higher interest expense. I think the increase in the normalized G&A only brings it up by less than a penny or something like that. So if there’s any further breakdown? And also with the dispositions, if you’re going to immediately redeploy those proceeds in the debt reduction, just trying to figure out, just any sort of quantification of the $0.04 by all the components might be helpful if you’re able to give some color on that. Thanks.

Certainly. The main factors to consider are the interest expense related to the higher average SOFR, which is a significant change from last quarter. Previously, we anticipated a decline in SOFR for the remainder of the year and into next year. Now, compared to our spring projections, we expect an increase of about 60 basis points in the average SOFR rate in the latter half of the year. Another key factor is labor inflation, which is affecting our same-store portfolio margins and the same-store NOI decline adjustment we've made. Additionally, there's an impact on general and administrative expenses. Lastly, we are adjusting non-cash straight-line rent to align with our current year performance and the anticipated additional property sales for the remainder of the year. The cash impact from these property dispositions will be minimal given our all-in cost is around 6.25, potentially slightly higher, and we anticipate selling cap rates on a cash basis around 6.5. Therefore, the impact from these factors, including some straight-line rent adjustments, forms the primary components of the overall change.

The next question comes from Connor Siversky from Wells Fargo.

Just a follow-up to the capital allocation and guidance questions. In the context of the heightened dispositions in the lowered guide, how should we be thinking about the dividend going into 2024?

Yes. I think on the dividend, Kris touched on it in prepared remarks. Certainly, our view is that we may be sort of in this current level of just over a 100% for the balance of the year, and we’re comfortable that the momentum we’re seeing going into ‘24 on the operational upside will put us back in a position below 100% on the payout. And certainly it’s early to say, but the macro environment has had obviously a tremendous impact on the overall picture, but we do see like many, a better picture of that looking ahead to ‘24. So, we see that as a potential tailwind. Obviously, we’ll revisit that after multiple Fed meetings and how we look at guidance going into ‘24. But I think our view from all of that is that we see the dividend as being sustainable for sure, and something that we can tolerate a little over a 100 for a bit while we capture this upside and really drive it well below a 100% next year.

And just a quick follow-up, can you just give us an update on the M&A environment following the updated guide for acquisitions and dispositions? How is the cap rate environment kind of influencing your appetite for deals at the moment?

Yes. I mean, I think what we’re seeing on the MOB transaction market right now, we’re seeing cap rates kind of stable for core assets in that low-6s range. We have seen some high-quality deals that have dipped below that. Generally though certainly volumes are down, but we’re seeing some decent activity there. We do see opportunity as lenders kind of get back into the space that we think that transaction volume will continue to be where it is and move up throughout the balance of the year and into next as interest rates are projected to come down. So I think there’s still an appetite out there for the product, just you’ve got an opportunity for some folks to kind of get in and achieve the higher IRRs that they’re targeting. But right now, we are seeing some folks that are going to sit on the sidelines. But still continuing to underwrite the space, looking for the right opportunities and looking for their moments. So, still a very attractive space.

I believe Rob touched on this in his prepared remarks, but the lending environment is crucial. We are noticing significant interest in medical office buildings from buyers who are willing to pay in cash and accept lower volume for the year, anticipating a more favorable lending environment ahead. Additionally, major lenders, particularly larger banks, are returning to this market without relying on regional banks. This signals positive trends, as these lenders are interested in the medical office sector due to its stability and reliability, which stands in sharp contrast to other sectors currently facing challenges. For instance, there’s been negative news about the apartment market as well. Clearly, lenders are gravitating towards the stability and safety offered by medical office buildings, which is benefiting the transaction market.

The next question comes from Mike Mueller from JP Morgan.

Can you comment on what’s the expected size of the seed portfolio that you’ll contribute? And then taking that into consideration, assuming it’s a ‘24 event, would you anticipate being a net seller again in 2024?

Mike, I would say, no change from what we said last quarter on the size of a seed portfolio, we sort of loosely laid out $500 million to $1 billion. I would say that’s certainly the target, obviously in this kind of market and as we engage with potential JV partners that can move around as you would expect. So I would still say that’s sort of the range we’re thinking about. I would also add certainly we’re looking at a structure that would probably lead us to be a smaller piece, maybe 20% to 30%. But again, that’s a flexible thing that will evolve through the process. So, sorry, what was your last question? Oh, our net seller position currently, will it continue into ‘24? I mean, obviously that’s largely dependent on the macro environment. It depends on where our cost of capital is. It depends on how things are moving for us. But I think we’re going to be very careful here and prudent here in terms of where our cost of capital is relative to where we can reinvest. But I think the JV certainly gives us, in addition to asset sales, an attractive source of capital that will have a lot of options to pursue all those different redeployment options, which is everything from share repurchase to development funding, debt repayment all of those. So, we’re pursuing those for now. And I think that will continue into ‘24 until we see something different.

The next question is from John Pawlowski from Green Street.

Kris, if the expense pressures you’re seeing persist, curious if there is risk to the 4% to 6% guidance for same-store next year?

We’ll just have to see how quickly it comes down and how much we’re able to recover as a pass-through, through the structures of the leases. So, as we get further along and we see how it’s adjusting, then we’ll analyze that as we start to put our expectations and formal guidance together for next year.

Setting aside guidance, just maybe you could elaborate on the expense pressures. Does it seem like a kind of a structural change in intermediate term growth of the expense profile of the business, or is it more transitory in your mind?

Yes. I’m wary of using that word because of what we saw from the Fed over the last few years. But I can speak a little bit to the trends. And what I can say that as I mentioned, right now, it still seems to be mostly on the labor side is what we’re seeing. And it is coming down. So, I want to make that clear. But it’s just not coming down quite as quickly. So year-over-year, in the first quarter labor in terms of personnel and janitorial was up almost 14%. In the second quarter it came down, but it was still year-over-year up 10%. So, we’re making progress but it just hasn’t come back to full historical level. So, as we continue to pass just difficult comps and things, we do feel like we’ll start to see that trend lower, but we are making some great progress in other portions of the expense structure that I think can help offset that. But we’ll continue to monitor that and work through that through the balance of the year.

Last question from me. Where are you aiming to get debt to EBITDA down to by the end of the year?

Our goal is to maintain a range of 6% to 6.5%, which is where we are currently. We anticipate being closer to the high end of that range by the end of the year, but we expect it to trend down next year as we see growth in cash flow. Additionally, we discussed last quarter that we have a couple of items we’re not currently recognizing income from, which we're working on selling and repaying. The sale of some assets and the repayment of another mezzanine loan will provide additional funds to pay down debt without affecting income. This will have a substantial impact, likely occurring late this year or early next year. However, by the end of the year, we still expect to be in the range of 6% to 6.5%.

As there are no further questions, I will now turn the call back over to the management team for any final comments.

Thank you, Adam. And thank you, everybody, for joining us this morning. We look forward to seeing many of you in Raleigh on October 5th in our Investor Day. And a reminder should be coming out soon. So, if you did not get one and are interested, please reach out to Ron and we’ll make sure you get an invitation. Thank you, everybody. Have a great day.

This concludes today’s call. Thank you very much for your attendance. You may now disconnect your lines.